Regeneron's COVID-19 antibody cocktail reduces hospitalization risk by 71%, study shows

Regeneron's COVID-19 antibody cocktail reduced the risk of COVID-19-associated hospitalization and death by 71 percent and lowered patients' viral loads faster than a placebo, according to results of a phase 3 clinical trial.